Renaissance Capital logo

Commentary & News

US IPO Week Ahead: Government shutdown looms over October IPO market


The October IPO market looks like it will be off to a quiet start, with no IPOs currently scheduled for the week ahead. The impending US government shutdown means it could stay that way. Leading the week’s potential headlines, luxury sandal brand Birkenstock (BIRK) is reportedly set to launch its US IPO on the first Monday of the month, with plans to more

US IPO Weekly Recap: Holdover Adlai Nortye leads 4 IPO week as more small deals enter the pipeline


The third quarter wrapped up with four IPOs and eight pipeline additions. Oncology biotech Adlai Nortye (ANL) raised $58 million at an $849 million market cap. The company originally planned to raise $72 million in August but never priced; it removed and then set new terms earlier this month. Operating through subsidiaries in the US and China, more

Cancer biotech Kairos Pharma files for an estimated $10 million IPO


Kairos Pharma, a Phase 2 biotech developing therapies for cancer, filed on Friday with the SEC for an initial public offering. The company did not disclose a proposed deal size, but we estimate the company could raise around $10 million. Kairos Pharma is focused on advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and more

French chronic disease biotech Abivax files for a $100 million US IPO


Abivax, a late-stage French biotech developing therapies for chronic inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is currently listed on the Euronext Paris under the symbol "ABVX". Abivax is focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate more